Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241527 · ClinicalTrials.gov registry record · Phase 3
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 556
- Enrollment target
NCT00241527: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00241527 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 556 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00241527, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 556 participants
- Enrollment target
Study Summary
This study was a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs placebo and esomeprazole 20 mg orally qd vs placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a treatment period of 4 weeks for relief of upper GI symptoms.
Interventions
- DRUG Esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 556 participants |
| Start Date | 2000-12 |
| Est. Completion | 2002-09 |
| Phase | Phase 3 |
What the finished NCT00241527 record still lists
NCT00241527 is an interventional study that assigns participants to a tested intervention. The registered 556 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 1 intervention - of which Esomeprazole is the first listed.
NCT00241527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00241527 about?
NCT00241527 is a clinical study titled "Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs". This study was a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs placebo and esomeprazole 20 mg orally qd vs placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a treatment p...
What is the current status of trial NCT00241527?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 556 participants. The study started on 2000-12. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00241527?
The interventions under investigation include: Esomeprazole (DRUG).
Who is sponsoring clinical trial NCT00241527?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00241527's enrollment target sits among peer trials
556 675th of 2000 higher than 1,325 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia